Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Ignite Creation Date:
2025-12-25 @ 12:21 AM
Ignite Modification Date:
2025-12-25 @ 10:25 PM
NCT ID:
NCT03742258
Description:
None
Frequency Threshold:
0
Time Frame:
Adverse Events (AEs) were collected over a 2 year period. Each patient was followed from the time of treatment, during treatment at the beginning of each cycle through 30 days post last treatment.
Study:
NCT03742258
Study Brief:
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Event Groups(If Any):
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| TAK-659 80mg + R-CHOP | Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV over 3-5 minutes, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning in cycle 2, patients also receive spleen tyrosine kinase inhibitor TAK-659 Dose Level 2 PO QD on days 1-21. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. | 0 | None | 2 | 3 | 3 | 3 | View |
| TAK-659 100mg + R-CHOP | Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV over 3-5 minutes, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning in cycle 2, patients also receive spleen tyrosine kinase inhibitor TAK-659 Dose Level 3 PO QD on days 1-21. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. | 1 | None | 6 | 6 | 6 | 6 | View |
| TAK-659 60mg + R-CHOP | Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV over 3-5 minutes, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning in cycle 2, patients also receive spleen tyrosine kinase inhibitor TAK-659 Dose Level 1 PO QD on days 1-21. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Prednisone: Given PO Rituximab: Given IV Spleen Tyrosine Kinase Inhibitor TAK-659: Given PO Vincristine Sulfate: Given IV | 0 | None | 0 | 3 | 3 | 3 | View |
Serious Events(If Any):
Serious Events
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Lung infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Sinusitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Febrile neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v5.0 | View |
| Atrial fibrillation | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v5.0 | View |
| Cardiac arrest | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v5.0 | View |
| Cardiac disorders - Other, specify | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v5.0 | View |
| Diarrhea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Bacteremia | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Endocarditis infective | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Infections and infestations - Other, specify | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Sepsis | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Thrush | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Hypokalemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Stroke | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v5.0 | View |
| Thromboembolic event | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v5.0 | View |
Other Events(If Any):
Other Events
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| White blood cell decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Anorexia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Dehydration | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Anemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v5.0 | View |
| Eye disorders - Other, specify | SYSTEMATIC_ASSESSMENT | Eye disorders | NCI CTCAE v5.0 | View |
| Constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Dry mouth | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Gastroesophageal reflux disease | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Chills | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v5.0 | View |
| Edema face | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v5.0 | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v5.0 | View |
| Non-cardiac chest pain | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v5.0 | View |
| Pain | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v5.0 | View |
| Laryngitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Skin infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Upper respiratory infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Infusion related reaction | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | NCI CTCAE v5.0 | View |
| Alanine aminotransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Alkaline phosphatase increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Aspartate aminotransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Blood bilirubin increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Blood lactate dehydrogenase increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Creatinine increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Electrocardiogram QT corrected interval prolonged | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Lymphocyte count decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Neutrophil count decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Serum amylase increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Weight loss | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Alopecia | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v5.0 | View |
| Pruritus | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v5.0 | View |
| Dry skin | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v5.0 | View |
| Hyperhidrosis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v5.0 | View |
| Cytomegalovirus infection reactivation | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Enterocolitis infectious | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Skin and subcutaneous tissue disorders - Other, specify | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v5.0 | View |
| Hypertension | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v5.0 | View |
| Palpitations | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v5.0 | View |
| Sinus tachycardia | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v5.0 | View |
| Tinnitus | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | NCI CTCAE v5.0 | View |
| Cataract | SYSTEMATIC_ASSESSMENT | Eye disorders | NCI CTCAE v5.0 | View |
| Floaters | SYSTEMATIC_ASSESSMENT | Eye disorders | NCI CTCAE v5.0 | View |
| Periorbital edema | SYSTEMATIC_ASSESSMENT | Eye disorders | NCI CTCAE v5.0 | View |
| Retinal vascular disorder | SYSTEMATIC_ASSESSMENT | Eye disorders | NCI CTCAE v5.0 | View |
| Abdominal pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Diarrhea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Ileus | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Facial pain | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v5.0 | View |
| Fever | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v5.0 | View |
| Hepatobiliary disorders - Other, specify | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | NCI CTCAE v5.0 | View |
| Bacteremia | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Conjunctivitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Sepsis | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Cardiac troponin I increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| GGT increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Lipase increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Lymphocyte count increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Platelet count decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Weight gain | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Hyperkalemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Hyperphosphatemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Hypokalemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Hypomagnesemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Arthralgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v5.0 | View |
| Back pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v5.0 | View |
| Chest wall pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v5.0 | View |
| Flank pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v5.0 | View |
| Muscle weakness lower limb | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v5.0 | View |
| Neck pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v5.0 | View |
| Headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v5.0 | View |
| Paresthesia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v5.0 | View |
| Peripheral sensory neuropathy | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v5.0 | View |
| Cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Hypoxia | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Pharyngolaryngeal pain | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Rhinorrhea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Wheezing | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Hyperglycemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Hyperuricemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Hypoalbuminemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Hypocalcemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Hyponatremia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Hypophosphatemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Bone pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v5.0 | View |
| Myalgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v5.0 | View |
| Concentration impairment | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v5.0 | View |
| Dysgeusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v5.0 | View |
| Peripheral motor neuropathy | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v5.0 | View |
| Anxiety | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v5.0 | View |
| Psychiatric disorders - Other, specify | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v5.0 | View |
| Allergic rhinitis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Dyspnea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Sleep apnea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Sore throat | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Edema limbs | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v5.0 | View |
| General disorders and administration site conditions - Other, specify | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v5.0 | View |
| Malaise | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v5.0 | View |
| Allergic reaction | SYSTEMATIC_ASSESSMENT | Immune system disorders | NCI CTCAE v5.0 | View |
| Hypotension | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v5.0 | View |
| Febrile neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v5.0 | View |
| Cardiac disorders - Other, specify | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v5.0 | View |
| Chest pain - cardiac | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v5.0 | View |
| Heart failure | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v5.0 | View |
| Sinus bradycardia | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v5.0 | View |
| Photophobia | SYSTEMATIC_ASSESSMENT | Eye disorders | NCI CTCAE v5.0 | View |
| Retinal tear | SYSTEMATIC_ASSESSMENT | Eye disorders | NCI CTCAE v5.0 | View |
| Retinopathy | SYSTEMATIC_ASSESSMENT | Eye disorders | NCI CTCAE v5.0 | View |
| Abdominal distension | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Colitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Dyspepsia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Dysphagia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Gastrointestinal disorders - Other, specify | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Mucositis oral | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Rectal pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v5.0 | View |
| Infections and infestations - Other, specify | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Lung infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Pharyngitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Thrush | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Urinary tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v5.0 | View |
| Bruising | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | NCI CTCAE v5.0 | View |
| Activated partial thromboplastin time prolonged | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Blood bicarbonate decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Ejection fraction decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| INR increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Investigations - Other, specify | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Urine output decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v5.0 | View |
| Acidosis | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Alkalosis | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Hypercalcemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Hypermagnesemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Hypernatremia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Hypoglycemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v5.0 | View |
| Arthritis | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v5.0 | View |
| Generalized muscle weakness | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v5.0 | View |
| Musculoskeletal and connective tissue disorder - Other, specify | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v5.0 | View |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | NCI CTCAE v5.0 | View |
| Dizziness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v5.0 | View |
| Lethargy | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v5.0 | View |
| Seizure | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v5.0 | View |
| Confusion | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v5.0 | View |
| Depression | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v5.0 | View |
| Insomnia | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v5.0 | View |
| Dysuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v5.0 | View |
| Hematuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v5.0 | View |
| Proteinuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v5.0 | View |
| Urinary frequency | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v5.0 | View |
| Urinary incontinence | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v5.0 | View |
| Urinary retention | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v5.0 | View |
| Reproductive system and breast disorders - Other, specify | SYSTEMATIC_ASSESSMENT | Reproductive system and breast disorders | NCI CTCAE v5.0 | View |
| Aspiration | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Atelectasis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Epistaxis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Hoarseness | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Nasal congestion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Pleural effusion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Productive cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Respiratory failure | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Respiratory, thoracic and mediastinal disorders - Other, specify | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v5.0 | View |
| Eczema | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v5.0 | View |
| Skin hyperpigmentation | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v5.0 | View |
| Skin ulceration | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v5.0 | View |
| Urticaria | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v5.0 | View |
| Vascular disorders - Other, specify | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v5.0 | View |
| Palmar-plantar erythrodysesthesia syndrome | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v5.0 | View |
| Rash acneiform | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v5.0 | View |
| Rash maculo-papular | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v5.0 | View |